News

September 14, 2017

Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis
INDIANAPOLIS, Sept. 14, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced new safety and efficacy data from a Phase 2 study of baricitinib in people with moderate-to-severe atopic dermatitis (AD). The results showed that baricitinib in combination with a mid-potency topical corticosteroid (...

September 12, 2017

Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control
RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 12, 2017 /PRNewswire/ -- New analyses of the landmark EMPA-REG OUTCOME® trial showed that Jardiance® (empagliflozin) tablets reduced the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, independent of blood sugar control at the start of the study....

September 11, 2017

Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress
INDIANAPOLIS, Sept. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that data across its immunology portfolio will be presented at the annual European Academy of Dermatology and Venereology Congress (EADV), including Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the treatment of moderate-to-severe...

September 10, 2017

Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer
INDIANAPOLIS, Sept. 10, 2017 /PRNewswire/ -- At the European Society for Medical Oncology (ESMO) 2017 Congress today, Phase 3 RANGE data from Eli Lilly and Company (NYSE: LLY) were presented in the Presidential Symposium (abstract#: LBA4_PR). These are the first detailed results from the global, randomized, double-blinded, placebo-controlled RANGE ...

September 9, 2017

IHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine
INDIANAPOLIS, Sept. 9, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present key primary and secondary endpoint data for lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, which demonstrated statistically significant improvements compared to placebo in the Phase 3 SPARTAN study. Detailed...

September 8, 2017

IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine
INDIANAPOLIS, Sept. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that treatment with self-administered galcanezumab for up to 12 months demonstrated a positive safety and tolerability profile in patients with migraine, consistent with previous studies. Detailed results from a 12-month, open-label Phase 3 study will be p...

September 6, 2017

Lilly to Present New Data for Galcanezumab and Lasmiditan at the 18th Congress of the International Headache Society (IHC)
INDIANAPOLIS, Sept. 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will present new data for galcanezumab and lasmiditan, two investigational treatments for migraine, at the 18th Congress of the International Headache Society (IHC) taking place Sept. 7-10 in Vancouver. Lilly will highlight new, long-term data f...

August 30, 2017

Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018
INDIANAPOLIS, Aug. 30, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that, after discussions with the U.S. Food and Drug Administration (FDA) in late August, Lilly will resubmit the New Drug Application (NDA) for baricitinib before the end of January 2018. The resubmission package will ...

August 29, 2017

New Phase 3 Data for Abemaciclib and Ramucirumab Presented at ESMO 2017 Congress
INDIANAPOLIS, Aug. 29, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will showcase new data across six different tumor types at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain, September 8-12, 2017. Notably, results from Phase 3 studies of abemaciclib and ramucirumab have been selected for oral presentation ...

August 4, 2017

Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine
INDIANAPOLIS, Aug. 4, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, met its primary endpoint in SPARTAN, a second Phase 3 study. At two hours following the first dose, a greater percentage of patients treated with lasmidi...

July 25, 2017

Lilly and Incyte Provide Update on Baricitinib
INDIANAPOLIS, July 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that a resubmission to the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA), wil...

July 12, 2017

Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference® 2017 (AAIC® 2017)
Data highlights include important health outcomes data emphasizing the need for timely detection and management of Alzheimer's disease INDIANAPOLIS, July 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will present findings from more than 40 research studies at the upcoming Alzheimer's Association Intern...

July 10, 2017

Renowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment
INDIANAPOLIS and RIDGEFIELD, Conn., July 10, 2017 /PRNewswire/ -- Popular television host and legendary entertainer, Don Francisco, is joining Lilly and Boehringer Ingelheim to launch a new awareness initiative, Basado en Hechos, to help address common misconceptions about type 2 diabetes and insulin treatment. As part of this partnership, ...

July 10, 2017

FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer
INDIANAPOLIS, July 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed its New Drug Application (NDA) for abemaciclib, a cyclin-dependent kinase (CDK)4 & 6 inhibitor, and given the NDA a Priority Review designation. The NDA includes the company's submissi...

July 3, 2017

Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis
INDIANAPOLIS, July 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for Olumiant® (baricitinib) 2-mg and 4-mg tablets for the treatment of rheumatoid arthritis (RA) (including the prevention of str...

June 27, 2017

Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour
INDIANAPOLIS, June 27, 2017 /PRNewswire/ -- For the 22,000 children who attend diabetes camp each year, feelings of isolation that may accompany type 1 diabetes can be overcome by fun experiences and new friends who say, "you are not alone." Lilly Diabetes understands the importance of the diabetes camp experience for those taking the first steps t...

June 16, 2017

EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks
INDIANAPOLIS, June 16, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) announced today that the majority of patients with active psoriatic arthritis (PsA) treated with Taltz® (ixekizumab) exhibited either no progression or minimal progression of radiographic structural joint damage through 52 weeks of treatment. Detailed results from the exten...

June 16, 2017

New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
INDIANAPOLIS, June 16, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced a new pooled analysis of data from eight Olumiant® (baricitinib) clinical trials, showing that baricitinib-treated and placebo-treated patients with moderate-to-severe rheumatoid arthritis (RA) had similar rates of serio...

June 15, 2017

EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors
Taltz also demonstrated significant improvements in key secondary measures at 24 weeks INDIANAPOLIS, June 15, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) announced today that patients with active psoriatic arthritis (PsA) who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors treated with T...

June 13, 2017

Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017)
INDIANAPOLIS, June 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data on safety and long-term efficacy from the Olumiant® (baricitinib) clinical trials will be presented in 21 abstracts, including one oral presentation, at the Annual European Congress of Rheumatology (...

Showing 1-20 of 37 Page: 1 2  Next 20